51
|
Carboxymethyl chitosan/phospholipid bilayer-capped mesoporous carbon nanoparticles with pH-responsive and prolonged release properties for oral delivery of the antitumor drug, Docetaxel. Int J Pharm 2017; 532:384-392. [DOI: 10.1016/j.ijpharm.2017.09.023] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2017] [Revised: 08/20/2017] [Accepted: 09/09/2017] [Indexed: 10/18/2022]
|
52
|
Hyaluronic acid coated PLGA nanoparticulate docetaxel effectively targets and suppresses orthotopic human lung cancer. J Control Release 2017; 259:76-82. [DOI: 10.1016/j.jconrel.2016.12.024] [Citation(s) in RCA: 67] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2016] [Accepted: 12/22/2016] [Indexed: 01/11/2023]
|
53
|
Sumera, Anwar A, Ovais M, Khan A, Raza A. Docetaxel‐loaded solid lipid nanoparticles: a novel drug delivery system. IET Nanobiotechnol 2017; 11:621-629. [PMCID: PMC8676273 DOI: 10.1049/iet-nbt.2017.0001] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2017] [Revised: 03/18/2017] [Accepted: 03/30/2017] [Indexed: 07/29/2023] Open
Abstract
Over the past few years, taxanes have emerged as a new class of anticancer drugs. Docetaxel (DTX) the prototype of this class has been approved for the treatment of broad range of cancers. However, to date the commercial preparation of DTX (Taxotere®) is accompanying adverse side effects, intolerance, and poor solubility, which can be overcome by encapsulating them using solid lipid nanoparticles (SLNs). SLNs represent versatile delivery system of drugs with newer forms such as polymer–solid lipid hybrid, surface modified and long circulating nanoparticles bringing forth improved prospects for cancer chemotherapy. In this review, the authors have discussed the current uses of various SLNs formulations of DTX with key emphasis on controlled and site‐specific drug delivery along with enhanced antitumour activity elucidated via in vitro and in vivo studies. Furthermore, the review article highlights few approaches that can be used in combination with existing DTX‐loaded SLNs to supplement DTX drug delivery.
Collapse
Affiliation(s)
- Sumera
- Department of PharmacyUniversity of SwabiSwabi23430Pakistan
| | - Amania Anwar
- Atta‐ur‐Rehman School of Applied BiosciencesNational University of Science and TechnologyIslamabad44000Pakistan
| | - Muhammad Ovais
- Department of BiotechnologyFaculty of Biological SciencesQuaid‐i‐Azam UniversityIslamabad45320Pakistan
| | - Abad Khan
- Department of PharmacyUniversity of SwabiSwabi23430Pakistan
| | - Abida Raza
- Nanotheragnostics LabNational Institute of Lasers and OptronicsPakistan Atomic Energy CommissionIslamabad44000Pakistan
| |
Collapse
|
54
|
Qureshi OS, Kim HS, Zeb A, Choi JS, Kim HS, Kwon JE, Kim MS, Kang JH, Ryou C, Park JS, Kim JK. Sustained release docetaxel-incorporated lipid nanoparticles with improved pharmacokinetics for oral and parenteral administration. J Microencapsul 2017; 34:250-261. [PMID: 28557649 DOI: 10.1080/02652048.2017.1337247] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
The aim of this study was to develop docetaxel-incorporated lipid nanoparticles (DTX-NPs) to improve the pharmacokinetic behaviour of docetaxel (DTX) after oral and parenteral administration via sustained release. DTX-NPs were prepared by nanotemplate engineering technique with palmityl alcohol as a solid lipid and Tween-40/Span-40/Myrj S40 as a surfactants mixture. Spherical DTX-NPs below 100 nm were successfully prepared with a narrow particle size distribution, 96% of incorporation efficiency and 686 times increase in DTX solubility. DTX-NPs showed a sustained release over 24 h in phosphate-buffered saline and simulated gastric and intestinal fluids, while DTX-micelles released DTX completely within 12 h. The half-maximal inhibitory concentration (IC50) of DTX-NPs against human breast cancer MCF-7 cells was 1.9 times lower than that of DTX-micelles and DTX solution. DTX-NPs demonstrated 3.7- and 2.8-fold increase in the area under the plasma concentration-time curve compared with DTX-micelles after oral and parenteral administration, respectively.
Collapse
Affiliation(s)
- Omer Salman Qureshi
- a College of Pharmacy, Institute of Pharmaceutical Science and Technology , Hanyang University , Ansan , Gyeonggi , Republic of Korea.,b Faculty of Pharmacy , The University of Lahore , Lahore , Punjab , Pakistan
| | - Hyung-Seo Kim
- a College of Pharmacy, Institute of Pharmaceutical Science and Technology , Hanyang University , Ansan , Gyeonggi , Republic of Korea
| | - Alam Zeb
- a College of Pharmacy, Institute of Pharmaceutical Science and Technology , Hanyang University , Ansan , Gyeonggi , Republic of Korea.,c Riphah Institute of Pharmaceutical Sciences , Riphah International University , Islamabad , Pakistan
| | - Jin-Seok Choi
- d College of Pharmacy , Chungnam National University , Daejeon , Republic of Korea
| | - Hoo-Seong Kim
- a College of Pharmacy, Institute of Pharmaceutical Science and Technology , Hanyang University , Ansan , Gyeonggi , Republic of Korea
| | - Jung-Eun Kwon
- a College of Pharmacy, Institute of Pharmaceutical Science and Technology , Hanyang University , Ansan , Gyeonggi , Republic of Korea
| | - Myung-Sic Kim
- a College of Pharmacy, Institute of Pharmaceutical Science and Technology , Hanyang University , Ansan , Gyeonggi , Republic of Korea
| | - Jong-Ho Kang
- a College of Pharmacy, Institute of Pharmaceutical Science and Technology , Hanyang University , Ansan , Gyeonggi , Republic of Korea
| | - Chongsuk Ryou
- a College of Pharmacy, Institute of Pharmaceutical Science and Technology , Hanyang University , Ansan , Gyeonggi , Republic of Korea
| | - Jeong-Sook Park
- d College of Pharmacy , Chungnam National University , Daejeon , Republic of Korea
| | - Jin-Ki Kim
- a College of Pharmacy, Institute of Pharmaceutical Science and Technology , Hanyang University , Ansan , Gyeonggi , Republic of Korea
| |
Collapse
|
55
|
Gallego-Yerga L, Posadas I, de la Torre C, Ruiz-Almansa J, Sansone F, Ortiz Mellet C, Casnati A, García Fernández JM, Ceña V. Docetaxel-Loaded Nanoparticles Assembled from β-Cyclodextrin/Calixarene Giant Surfactants: Physicochemical Properties and Cytotoxic Effect in Prostate Cancer and Glioblastoma Cells. Front Pharmacol 2017; 8:249. [PMID: 28533751 PMCID: PMC5420566 DOI: 10.3389/fphar.2017.00249] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2016] [Accepted: 04/19/2017] [Indexed: 01/26/2023] Open
Abstract
Giant amphiphiles encompassing a hydrophilic β-cyclodextrin (βCD) component and a hydrophobic calix[4]arene (CA4) module undergo self-assembly in aqueous media to afford core-shell nanospheres or nanocapsules, depending on the nanoprecipitation protocol, with high docetaxel (DTX) loading capacity. The blank and loaded nanoparticles have been fully characterized by dynamic light scattering (DLS), ζ-potential measurements and cryo-transmission electron microscopy (cryo-TEM). The data are compatible with the distribution of the drug between the nanoparticle core and the shell, where it is probably anchored by inclusion of the DTX aromatic moieties in βCD cavities. Indeed, the release kinetics profiles evidenced an initial fast release of the drug, which likely accounts for the fraction hosted on the surface, followed by a slow and sustained release rate, corresponding to diffusion of DTX in the core, which can be finely tuned by modification of the giant amphiphile chemical structure. The ability of the docetaxel-loaded nanoparticles to induce cellular death in different prostate (human LnCap and PC3) and glioblastoma (human U87 and rat C6) cells was also explored. Giant amphiphile-based DTX formulations surpassing or matching the antitumoral activity of the free DTX formulation were identified in all cases with no need to employ any organic co-solvent, thus overcoming the DTX water solubility problems. Moreover, the presence of the βCD shell at the surface of the assemblies is intended to impart stealth properties against serum proteins while permitting nanoparticle surface decoration by supramolecular approaches, paving the way for a new generation of molecularly well-defined antitumoral drug delivery systems with improved specificity and efficiency. Altogether, the results provide a proof of concept of the suitability of the approach based on βCD-CA4 giant amphiphiles to access DTX carriers with tunable properties.
Collapse
Affiliation(s)
- Laura Gallego-Yerga
- Departamento de Química Orgánica, Facultad de Química, Universidad de SevillaSevilla, Spain
| | - Inmaculada Posadas
- CIBERNED, Instituto de Salud Carlos IIIMadrid, Spain.,Unidad Asociada Neurodeath, Facultad de Medicina, Universidad de Castilla-La ManchaAlbacete, Spain
| | - Cristina de la Torre
- CIBERNED, Instituto de Salud Carlos IIIMadrid, Spain.,Unidad Asociada Neurodeath, Facultad de Medicina, Universidad de Castilla-La ManchaAlbacete, Spain
| | - Jesús Ruiz-Almansa
- CIBERNED, Instituto de Salud Carlos IIIMadrid, Spain.,Unidad Asociada Neurodeath, Facultad de Medicina, Universidad de Castilla-La ManchaAlbacete, Spain
| | - Francesco Sansone
- Dipartimento di Chimica, Università degli Studi di ParmaParma, Italy
| | - Carmen Ortiz Mellet
- Departamento de Química Orgánica, Facultad de Química, Universidad de SevillaSevilla, Spain
| | | | | | - Valentín Ceña
- CIBERNED, Instituto de Salud Carlos IIIMadrid, Spain.,Unidad Asociada Neurodeath, Facultad de Medicina, Universidad de Castilla-La ManchaAlbacete, Spain
| |
Collapse
|
56
|
Zhang L, Yang X, Lv Y, Xin X, Qin C, Han X, Yang L, He W, Yin L. Cytosolic co-delivery of miRNA-34a and docetaxel with core-shell nanocarriers via caveolae-mediated pathway for the treatment of metastatic breast cancer. Sci Rep 2017; 7:46186. [PMID: 28383524 PMCID: PMC5382875 DOI: 10.1038/srep46186] [Citation(s) in RCA: 59] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2016] [Accepted: 03/10/2017] [Indexed: 01/19/2023] Open
Abstract
Co-delivery of microRNAs and chemotherapeutic drugs into tumor cells is an attractive strategy for synergetic breast cancer therapy due to their complementary mechanisms. In this work, a core-shell nanocarrier coated by cationic albumin was developed to simultaneously deliver miRNA-34a and docetaxel (DTX) into breast cancer cells for improved therapeutic effect. The co-delivery nanocarriers showed a spherical morphology with an average particle size of 183.9 nm, and they efficiently protected miRNA-34a from degradation by RNase and serum. Importantly, the nanocarriers entered the cytosol via a caveolae-mediated pathway without entrapment in endosomes/lysosomes, thus improving the utilization of the cargo. In vitro, the co-delivery nanocarriers suppressed the expression of anti-apoptosis gene Bcl-2 at both transcription and protein levels, inhibited tumor cell migration and efficiently induced cell apoptosis and cytotoxicity. In vivo, the co-delivery nanocarriers prolonged the blood circulation of DTX, enhanced tumor accumulation of the cargo and significantly inhibited tumor growth and metastasis in 4T1-tumor bearing mice models. Taken together, the present nanocarrier co-loading with DTX and miRNA-34a is a new nanoplatform for the combination of insoluble drugs and gene/protein drugs and provides a promising strategy for the treatment of metastatic breast cancer.
Collapse
Affiliation(s)
- Li Zhang
- Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, P.R. China.,Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, China Pharmaceutical University, Nanjing 210009, P.R. China
| | - Xin Yang
- Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, P.R. China.,Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, China Pharmaceutical University, Nanjing 210009, P.R. China
| | - Yaqi Lv
- Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, P.R. China.,Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, China Pharmaceutical University, Nanjing 210009, P.R. China
| | - Xiaofei Xin
- Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, P.R. China.,Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, China Pharmaceutical University, Nanjing 210009, P.R. China
| | - Chao Qin
- Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, P.R. China.,Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, China Pharmaceutical University, Nanjing 210009, P.R. China
| | - Xiaopeng Han
- Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, P.R. China.,Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, China Pharmaceutical University, Nanjing 210009, P.R. China
| | - Lei Yang
- Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, P.R. China.,Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, China Pharmaceutical University, Nanjing 210009, P.R. China
| | - Wei He
- Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, P.R. China.,Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, China Pharmaceutical University, Nanjing 210009, P.R. China
| | - Lifang Yin
- Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, P.R. China.,Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, China Pharmaceutical University, Nanjing 210009, P.R. China
| |
Collapse
|
57
|
Zhang L, Xiao Q, Wang Y, Zhang C, He W, Yin L. Denatured protein-coated docetaxel nanoparticles: Alterable drug state and cytosolic delivery. Int J Pharm 2017; 523:1-14. [PMID: 28323094 DOI: 10.1016/j.ijpharm.2017.03.026] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2016] [Revised: 02/28/2017] [Accepted: 03/13/2017] [Indexed: 11/25/2022]
Abstract
Many lead compounds have a low solubility in water, which substantially hinders their clinical application. Nanosuspensions have been considered a promising strategy for the delivery of water-insoluble drugs. Here, denatured soy protein isolate (SPI)-coated docetaxel nanosuspensions (DTX-NS) were developed using an anti-solvent precipitation-ultrasonication method to improve the water-solubility of DTX, thus improving its intracellular delivery. DTX-NS, with a diameter of 150-250nm and drug-loading up to 18.18%, were successfully prepared by coating drug particles with SPI. Interestingly, the drug state of DTX-NS was alterable. Amorphous drug nanoparticles were obtained at low drug-loading, whereas at a high drug-loading, the DTX-NS drug was mainly present in the crystalline state. Moreover, DTX-NS could be internalized at high levels by cancer cells and enter the cytosol by lysosomal escape, enhancing cell cytotoxicity and apoptosis compared with free DTX. Taken together, denatured SPI has a strong stabilization effect on nanosuspensions, and the drug state in SPI-coated nanosuspensions is alterable by changing the drug-loading. Moreover, DTX-NS could achieve cytosolic delivery, generating enhanced cell cytotoxicity against cancer cells.
Collapse
Affiliation(s)
- Li Zhang
- Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, PR China
| | - Qingqing Xiao
- Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, PR China
| | - Yiran Wang
- Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, PR China
| | - Chenshuang Zhang
- Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, PR China
| | - Wei He
- Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, PR China.
| | - Lifang Yin
- Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, PR China.
| |
Collapse
|
58
|
|
59
|
Li J, Cheng X, Chen Y, He W, Ni L, Xiong P, Wei M. Vitamin E TPGS modified liposomes enhance cellular uptake and targeted delivery of luteolin: An in vivo/in vitro evaluation. Int J Pharm 2016; 512:262-272. [DOI: 10.1016/j.ijpharm.2016.08.037] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2016] [Revised: 08/01/2016] [Accepted: 08/17/2016] [Indexed: 01/12/2023]
|
60
|
Cadete A, Alonso MJ. Targeting cancer with hyaluronic acid-based nanocarriers: recent advances and translational perspectives. Nanomedicine (Lond) 2016; 11:2341-57. [PMID: 27526874 DOI: 10.2217/nnm-2016-0117] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023] Open
Abstract
Hyaluronic acid is a natural polysaccharide that has been widely explored for the development of anticancer therapies due to its ability to target cancer cells. Moreover, advances made in the last decade have revealed the versatility of this biomaterial in the design of multifunctional carriers, intended for the delivery of a variety of bioactive molecules, including polynucleotides, immunomodulatory drugs and imaging agents. In this review, we aim to provide an overview of the major recent achievements in this field, highlighting the application of the newly developed nanostructures in combination therapies, immunomodulation and theranostics. Finally, we will discuss the main challenges and technological advances that will allow these carriers to be considered as candidates for clinical development.
Collapse
Affiliation(s)
- Ana Cadete
- NanoBioFar Group, Center for Research in Molecular Medicine & Chronic Diseases, Health Research Institute of Santiago de Compostela (IDIS), Department of Pharmacy & Pharmaceutical Technology, School of Pharmacy, Campus Vida, University of Santiago de Compostela (USC), Avenida Barcelona s/n, 15782 Santiago de Compostela, Spain
| | - María José Alonso
- NanoBioFar Group, Center for Research in Molecular Medicine & Chronic Diseases, Health Research Institute of Santiago de Compostela (IDIS), Department of Pharmacy & Pharmaceutical Technology, School of Pharmacy, Campus Vida, University of Santiago de Compostela (USC), Avenida Barcelona s/n, 15782 Santiago de Compostela, Spain
| |
Collapse
|
61
|
Luque-Michel E, Imbuluzqueta E, Sebastián V, Blanco-Prieto MJ. Clinical advances of nanocarrier-based cancer therapy and diagnostics. Expert Opin Drug Deliv 2016; 14:75-92. [PMID: 27339650 DOI: 10.1080/17425247.2016.1205585] [Citation(s) in RCA: 52] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
INTRODUCTION Cancer is a leading cause of death worldwide and efficient new strategies are urgently needed to combat its high mortality and morbidity statistics. Fortunately, over the years, nanotechnology has evolved as a frontrunner in the areas of imaging, diagnostics and therapy, giving the possibility of monitoring, evaluating and individualizing cancer treatments in real-time. Areas covered: Polymer-based nanocarriers have been extensively studied to maximize cancer treatment efficacy and minimize the adverse effects of standard therapeutics. Regarding diagnosis, nanomaterials like quantum dots, iron oxide nanoparticles or gold nanoparticles have been developed to provide rapid, sensitive detection of cancer and, therefore, facilitate early treatment and monitoring of the disease. Therefore, multifunctional nanosystems with both imaging and therapy functionalities bring us a step closer to delivering precision/personalized medicine in the cancer setting. Expert opinion: There are multiple barriers for these new nanosystems to enter the clinic, but it is expected that in the near future, nanocarriers, together with new 'targeted drugs', could replace our current treatments and cancer could become a nonfatal disease with good recovery rates. Joint efforts between scientists, clinicians, the pharmaceutical industry and legislative bodies are needed to bring to fruition the application of nanosystems in the clinical management of cancer.
Collapse
Affiliation(s)
- Edurne Luque-Michel
- a Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy and Nutrition , University of Navarra , Pamplona , Spain.,b IdiSNA, Fundación Instituto de Investigación Sanitaria de Navarra , Recinto del Complejo Hospitalario de Navarra , Pamplona , Spain
| | - Edurne Imbuluzqueta
- a Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy and Nutrition , University of Navarra , Pamplona , Spain.,b IdiSNA, Fundación Instituto de Investigación Sanitaria de Navarra , Recinto del Complejo Hospitalario de Navarra , Pamplona , Spain
| | - Víctor Sebastián
- c Institute of Nanoscience of Aragon (INA) and Department of Chemical, Engineering and Environmental Technology , University of Zaragoza , Zaragoza , Spain.,d CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN) , Centro de Investigación Biomédica en Red , Madrid , Spain
| | - María J Blanco-Prieto
- a Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy and Nutrition , University of Navarra , Pamplona , Spain.,b IdiSNA, Fundación Instituto de Investigación Sanitaria de Navarra , Recinto del Complejo Hospitalario de Navarra , Pamplona , Spain
| |
Collapse
|
62
|
Nagesh PKB, Johnson NR, Boya VKN, Chowdhury P, Othman SF, Khalilzad-Sharghi V, Hafeez BB, Ganju A, Khan S, Behrman SW, Zafar N, Chauhan SC, Jaggi M, Yallapu MM. PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer. Colloids Surf B Biointerfaces 2016; 144:8-20. [PMID: 27058278 DOI: 10.1016/j.colsurfb.2016.03.071] [Citation(s) in RCA: 85] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2016] [Revised: 03/22/2016] [Accepted: 03/24/2016] [Indexed: 01/22/2023]
Abstract
Docetaxel (Dtxl) is currently the most common therapeutic option for prostate cancer (PC). However, adverse side effects and problems associated with chemo-resistance limit its therapeutic outcome in clinical settings. A targeted nanoparticle system to improve its delivery to and activity at the tumor site could be an attractive strategy for PC therapy. Therefore, the objective of this study was to develop and determine the anti-cancer efficacy of a novel docetaxel loaded, prostate specific membrane antigen (PSMA) targeted superparamagnetic iron oxide nanoparticle (SPION) (J591-SPION-Dtxl) formulation for PC therapy. Our results showed the SPION-Dtxl formulation exhibits an optimal particle size and zeta potential, which can efficiently be internalized in PC cells. SPION-Dtxl exhibited potent anti-cancer efficacy via induction of the expression of apoptosis associated proteins, downregulation of anti-apoptotic proteins, and inhibition of chemo-resistance associated protein in PC cell lines. J591-SPION-Dtxl exhibited a profound uptake in C4-2 (PSMA(+)) cells compared to PC-3 (PSMA(-)) cells. A similar targeting potential was observed in ex-vivo studies in C4-2 tumors but not in PC-3 tumors, suggesting its tumor specific targeting. Overall, this study suggests that a PSMA antibody functionalized SPION-Dtxl formulation can be highly useful for targeted PC therapy.
Collapse
Affiliation(s)
- Prashanth K B Nagesh
- Department of Pharmaceutical Sciences and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN, USA
| | - Nia R Johnson
- Department of Pharmaceutical Sciences and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN, USA
| | - Vijaya K N Boya
- Department of Pharmaceutical Sciences and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN, USA
| | - Pallabita Chowdhury
- Department of Pharmaceutical Sciences and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN, USA
| | - Shadi F Othman
- Department of Biological Systems Engineering, University of Nebraska-Lincoln, Lincoln, NE, USA
| | - Vahid Khalilzad-Sharghi
- Department of Biological Systems Engineering, University of Nebraska-Lincoln, Lincoln, NE, USA
| | - Bilal B Hafeez
- Department of Pharmaceutical Sciences and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN, USA
| | - Aditya Ganju
- Department of Pharmaceutical Sciences and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN, USA
| | - Sheema Khan
- Department of Pharmaceutical Sciences and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN, USA
| | - Stephen W Behrman
- Department of Surgery, College of Medicine, University of Tennessee Health Science Center, Memphis, TN, USA
| | - Nadeem Zafar
- Department of Pathology, College of Medicine, University of Tennessee at Memphis, Memphis, TN, USA
| | - Subhash C Chauhan
- Department of Pharmaceutical Sciences and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN, USA
| | - Meena Jaggi
- Department of Pharmaceutical Sciences and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN, USA.
| | - Murali M Yallapu
- Department of Pharmaceutical Sciences and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN, USA.
| |
Collapse
|
63
|
Lakshmanan VK. Therapeutic efficacy of nanomedicines for prostate cancer: An update. Investig Clin Urol 2016; 57:21-9. [PMID: 26966723 PMCID: PMC4778751 DOI: 10.4111/icu.2016.57.1.21] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2015] [Accepted: 12/09/2015] [Indexed: 02/06/2023] Open
Abstract
Recent advances in cancer nanomedicine have attracted remarkable attention in medical sectors. Pharmacologic research on nanomedicines, including targeted cancer therapy, has increased dramatically in the past 5 years. The success stories of nanomedicines in the clinical field include the fabrication of nanomedicines that show maximum loading efficiency into carriers, maximal release kinetics, and minimum toxicity to healthy cells. Nanoparticle-mediated medicines have been developed to specifically target prostate cancer tissue by use of aptamers, antibody targeting, and sustained release of nanomedicines in a dose- and time-dependent manner. Nanomedicines have been developed for therapeutic application in combination with image-guided therapy in real time. The scope of one of these nanomedicines, Abraxane (paclitaxel), may be extended to prostate cancer therapeutic applications for better quality of patient life and longer survival. This review provides an update on the latest directions and developments in nanomedicines for prostate cancer.
Collapse
Affiliation(s)
- Vinoth-Kumar Lakshmanan
- Department of Biomedical Sciences, Chonnam National University Medical School, Gwangju, Korea
| |
Collapse
|
64
|
Yu X, Zhang B, Wang T, Zhang J, Mu S, Liu C, Zhang N. Two-stage pH-sensitive doxorubicin hydrochloride loaded core–shell nanoparticles with dual drug-loading strategies for the potential anti-tumor treatment. RSC Adv 2016. [DOI: 10.1039/c6ra19242d] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Two-stage pH-sensitive DOX·HCl loaded core–shell nanoparticles (CPOD) with dual drug-loading strategies showed pretty in vivo anti-tumor efficacy.
Collapse
Affiliation(s)
- Xiaoyue Yu
- Department of Pharmaceutics
- School of Pharmaceutical Science
- Shandong University
- Jinan 250012
- China
| | - Bo Zhang
- Department of Pharmaceutics
- School of Pharmaceutical Science
- Shandong University
- Jinan 250012
- China
| | - Tianqi Wang
- Department of Pharmaceutics
- School of Pharmaceutical Science
- Shandong University
- Jinan 250012
- China
| | - Jing Zhang
- Department of Pharmaceutics
- School of Pharmaceutical Science
- Shandong University
- Jinan 250012
- China
| | - Shengjun Mu
- Department of Pharmaceutics
- School of Pharmaceutical Science
- Shandong University
- Jinan 250012
- China
| | - Chunxi Liu
- Pharmaceutical Department
- Qilu Hospital of Shandong University
- Jinan 250012
- China
| | - Na Zhang
- Department of Pharmaceutics
- School of Pharmaceutical Science
- Shandong University
- Jinan 250012
- China
| |
Collapse
|
65
|
Su Z, Liang Y, Yao Y, Wang T, Zhang N. Polymeric complex micelles based on the double-hydrazone linkage and dual drug-loading strategy for pH-sensitive docetaxel delivery. J Mater Chem B 2016; 4:1122-1133. [DOI: 10.1039/c5tb02188j] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Complex micelles, which integrated double-hydrazone linkage and dual drug-loading patterns, were constructed for the first time.
Collapse
Affiliation(s)
- Zhihui Su
- Department of Pharmaceutics
- School of Pharmaceutical Science
- Shandong University
- Ji'nan 250012
- China
| | - Yanchao Liang
- Department of Pharmaceutics
- School of Pharmaceutical Science
- Shandong University
- Ji'nan 250012
- China
| | - Yao Yao
- Department of Pharmaceutics
- School of Pharmaceutical Science
- Shandong University
- Ji'nan 250012
- China
| | - Tianqi Wang
- Department of Pharmaceutics
- School of Pharmaceutical Science
- Shandong University
- Ji'nan 250012
- China
| | - Na Zhang
- Department of Pharmaceutics
- School of Pharmaceutical Science
- Shandong University
- Ji'nan 250012
- China
| |
Collapse
|
66
|
Jain A, Thakur K, Sharma G, Kush P, Jain UK. Fabrication, characterization and cytotoxicity studies of ionically cross-linked docetaxel loaded chitosan nanoparticles. Carbohydr Polym 2015; 137:65-74. [PMID: 26686106 DOI: 10.1016/j.carbpol.2015.10.012] [Citation(s) in RCA: 76] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2015] [Revised: 10/01/2015] [Accepted: 10/04/2015] [Indexed: 12/20/2022]
Abstract
The present investigation aimed at the fabrication and characterization of ionically cross-linked docetaxel (DTX) loaded chitosan nanoparticles (DTX-CH-NP) using ionic gelation technique with sodium tripolyphosphate (TPP) as the cross-linking agent. The formulated nanoparticles were characterized in terms of particle size, drug entrapment efficiency (EE), scanning electron microscopy (SEM), in vitro release and cytotoxicity studies. Formulation factors (chitosan, TPP and drug concentration) were examined systematically for their effects on size of the nanoparticles. The average size of the nanoparticles was observed to be in the range of 159.2 ± 3.31 to 220.7 ± 2.23 nm with 78-92% encapsulation efficiency (EE). The in vitro cytotoxicity studies on breast cancer cell lines (MDA-MB-231) revealed the advantages of DTX-CH-NP over pure DTX with approximately 85% cell viability reduction. The results indicate that systematic modulation of the surface charge and particle size of ionically cross-linked nanoparticles can be readily achieved with the right control of critical processing parameters. Thus, DTX-CH-NP presents a promising delivery alternative for breast cancer treatment.
Collapse
Affiliation(s)
- Ankit Jain
- Department of Pharmaceutics, Chandigarh College of Pharmacy, Mohali 140110, India.
| | - Kanika Thakur
- University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Studies, Panjab University, Chandigarh 160014, India
| | - Gajanand Sharma
- University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Studies, Panjab University, Chandigarh 160014, India
| | - Preeti Kush
- Department of Pharmaceutics, Chandigarh College of Pharmacy, Mohali 140110, India
| | - Upendra K Jain
- Department of Pharmaceutics, Chandigarh College of Pharmacy, Mohali 140110, India
| |
Collapse
|
67
|
Kim TK, Yoo HH. Anticancer effect of docetaxel/hydroxypropyl-beta-cyclodextrin complex without histamine release. J INCL PHENOM MACRO 2015. [DOI: 10.1007/s10847-015-0571-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
68
|
Zhang L, Liu T, Xiao Y, Yu D, Zhang N. Hyaluronic Acid-Chitosan Nanoparticles to Deliver Gd-DTPA for MR Cancer Imaging. NANOMATERIALS (BASEL, SWITZERLAND) 2015; 5:1379-1396. [PMID: 28347070 PMCID: PMC5304629 DOI: 10.3390/nano5031379] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/01/2015] [Revised: 07/28/2015] [Accepted: 08/13/2015] [Indexed: 01/17/2023]
Abstract
Molecular imaging is essential to increase the sensitivity and selectivity of cancer diagnosis especially at the early stage of tumors. Recently, polyionic nanocomplexes (PICs), which are composed of polyanions and opposite polycations, have been demonstrated to be a promising strategy for biomedical applications. In this work, chitosan-hyaluronic acid nanoparticles (GCHN) were developed to deliver Gd-DTPA as MRI contrast agents for tumor diagnosis. The Gd-labeled conjugates (CS-DTPA-Gd) were successfully synthesized by carbodiimide reaction, and then GCHN were prepared by ionic gelation using the obtained CS-DTPA-Gd and hyaluronic acid. The morphology of GCHN was spherical or ellipsoidal, which is observed by transmission electronic microscopy (TEM). The mean particle size and zeta potential of GCHN were 213.8 ± 2.6 nm and 19.92 ± 1.69 mV, respectively. The significant enhancement of signal intensity induced by GCHN was observed both in vitro and in vivo. Also, compared with Magnevist, GCHN was witnessed for a prolonged imaging time in the B16 tumor-bearing mice model. Furthermore, GCHN were verified as below toxic both in vitro and in vivo. These results indicated that GCHN could potentially be an alternative to current MRI contrast agents for tumor diagnosis.
Collapse
Affiliation(s)
- Li Zhang
- Department of Pharmaceutics, School of Pharmaceutical Science, Shandong University, Ji'nan 250012, China.
| | - Tingxian Liu
- Department of Pharmaceutics, School of Pharmaceutical Science, Shandong University, Ji'nan 250012, China.
| | - Yanan Xiao
- Department of Pharmaceutics, School of Pharmaceutical Science, Shandong University, Ji'nan 250012, China.
| | - Dexin Yu
- Department of Radiology Medicine, Affiliated Qilu Hospital, Shandong University, Ji'nan 250012, China.
| | - Na Zhang
- Department of Pharmaceutics, School of Pharmaceutical Science, Shandong University, Ji'nan 250012, China.
| |
Collapse
|
69
|
Biffi S, Voltan R, Rampazzo E, Prodi L, Zauli G, Secchiero P. Applications of nanoparticles in cancer medicine and beyond: optical and multimodal in vivo imaging, tissue targeting and drug delivery. Expert Opin Drug Deliv 2015; 12:1837-49. [PMID: 26289673 DOI: 10.1517/17425247.2015.1071791] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
INTRODUCTION Nanotechnology has opened up the way to the engineering of new organized materials endowed with improved performances. In the past decade, engineered nanoparticles (NPs) have been progressively implemented by exploiting synthetic strategies that yield complex materials capable of performing functions with applications also in medicine. Indeed, in the field of 'nanomedicine' it has been explored the possibility to design multifunctional nanosystems, characterized by high analytical performances and stability, low toxicity and specificity towards a given cell target. AREA COVERED In this review article, we summarize the advances in the engineering of NPs for biomedical applications, from optical imaging (OI) to multimodal OI and targeted drug delivery. For this purpose, we will provide some examples of how investigations in nanomedicine can support preclinical and clinical research generating innovative diagnostic and therapeutic strategies in oncology. EXPERT OPINION The progressive breakthroughs in nanomedicine have supported the development of multifunctional and multimodal NPs. In particular, NPs are significantly impacting the diagnostic and therapeutic strategies since they allow the development of: NP-based OI probes containing more than one modality-specific contrast agent; surface functionalized NPs for specific 'molecular recognition'. Therefore, the design and characterization of innovative NP-based systems/devices have great applicative potential into the medical field.
Collapse
Affiliation(s)
- Stefania Biffi
- a 1 Institute for Maternal and Child Health - IRCCS "Burlo Garofolo" , via dell'Istria, 65/1, 34137 Trieste, Italy +39 040 3757722 ; +39 040 3785210 ;
| | - Rebecca Voltan
- b 2 University of Ferrara, LTTA Centre, Department of Morphology, Surgery and Experimental Medicine , Via Fossato di Mortara 70, 44121 Ferrara, Italy
| | - Enrico Rampazzo
- c 3 University of Bologna, Department of Chemistry "G. Ciamician" , Via Selmi 2, 40126 Bologna, Italy
| | - Luca Prodi
- d 4 University of Bologna, Department of Chemistry "G. Ciamician" , Via Selmi 2, 40126 Bologna, Italy
| | - Giorgio Zauli
- e 5 Institute for Maternal and Child Health - IRCCS "Burlo Garofolo" , via dell'Istria, 65/1, 34137 Trieste, Italy +39 040 3785478 ; +39 040 3785210;
| | - Paola Secchiero
- f 6 University of Ferrara, LTTA Centre, Department of Morphology, Surgery and Experimental Medicine , Via Fossato di Mortara 70, 44121 Ferrara, Italy
| |
Collapse
|
70
|
Cyclic-RGDfK peptide conjugated succinoyl-TPGS nanomicelles for targeted delivery of docetaxel to integrin receptor over-expressing angiogenic tumours. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2015; 11:1511-20. [DOI: 10.1016/j.nano.2015.04.007] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/26/2014] [Revised: 03/15/2015] [Accepted: 04/10/2015] [Indexed: 12/21/2022]
|
71
|
Hu Q, Rijcken CJ, Bansal R, Hennink WE, Storm G, Prakash J. Complete regression of breast tumour with a single dose of docetaxel-entrapped core-cross-linked polymeric micelles. Biomaterials 2015; 53:370-8. [DOI: 10.1016/j.biomaterials.2015.02.085] [Citation(s) in RCA: 68] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2014] [Revised: 02/18/2015] [Accepted: 02/19/2015] [Indexed: 10/23/2022]
|
72
|
Shang HB, Chen F, Wu J, Qi C, Lu BQ, Chen X, Zhu YJ. Multifunctional biodegradable terbium-doped calcium phosphate nanoparticles: facile preparation, pH-sensitive drug release and in vitro bioimaging. RSC Adv 2014. [DOI: 10.1039/c4ra09902h] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
|
73
|
Drug delivery nanoparticles in skin cancers. BIOMED RESEARCH INTERNATIONAL 2014; 2014:895986. [PMID: 25101298 PMCID: PMC4102061 DOI: 10.1155/2014/895986] [Citation(s) in RCA: 91] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/26/2013] [Accepted: 04/28/2014] [Indexed: 12/17/2022]
Abstract
Nanotechnology involves the engineering of functional systems at nanoscale, thus being attractive for disciplines ranging from materials science to biomedicine. One of the most active research areas of the nanotechnology is nanomedicine, which applies nanotechnology to highly specific medical interventions for prevention, diagnosis, and treatment of diseases, including cancer disease. Over the past two decades, the rapid developments in nanotechnology have allowed the incorporation of multiple therapeutic, sensing, and targeting agents into nanoparticles, for detection, prevention, and treatment of cancer diseases. Nanoparticles offer many advantages as drug carrier systems since they can improve the solubility of poorly water-soluble drugs, modify pharmacokinetics, increase drug half-life by reducing immunogenicity, improve bioavailability, and diminish drug metabolism. They can also enable a tunable release of therapeutic compounds and the simultaneous delivery of two or more drugs for combination therapy. In this review, we discuss the recent advances in the use of different types of nanoparticles for systemic and topical drug delivery in the treatment of skin cancer. In particular, the progress in the treatment with nanocarriers of basal cell carcinoma, squamous cell carcinoma, and melanoma has been reported.
Collapse
|
74
|
Evaluation of the peripheral analgesic effect of sufentanil lipid nanoparticles. J Anesth 2014; 28:702-7. [DOI: 10.1007/s00540-014-1795-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2013] [Accepted: 01/19/2014] [Indexed: 10/25/2022]
|
75
|
Abstract
Recent advances in nanotechnology and biotechnology have contributed to the development of engineered nanoscale materials as innovative prototypes to be used for biomedical applications and optimized therapy. Due to their unique features, including a large surface area, structural properties, and a long circulation time in blood compared with small molecules, a plethora of nanomaterials has been developed, with the potential to revolutionize the diagnosis and treatment of several diseases, in particular by improving the sensitivity and recognition ability of imaging contrast agents and by selectively directing bioactive agents to biological targets. Focusing on cancer, promising nanoprototypes have been designed to overcome the lack of specificity of conventional chemotherapeutic agents, as well as for early detection of precancerous and malignant lesions. However, several obstacles, including difficulty in achieving the optimal combination of physicochemical parameters for tumor targeting, evading particle clearance mechanisms, and controlling drug release, prevent the translation of nanomedicines into therapy. In spite of this, recent efforts have been focused on developing functionalized nanoparticles for delivery of therapeutic agents to specific molecular targets overexpressed on different cancer cells. In particular, the combination of targeted and controlled-release polymer nanotechnologies has resulted in a new programmable nanotherapeutic formulation of docetaxel, namely BIND-014, which recently entered Phase II clinical testing for patients with solid tumors. BIND-014 has been developed to overcome the limitations facing delivery of nanoparticles to many neoplasms, and represents a validated example of targeted nanosystems with the optimal biophysicochemical properties needed for successful tumor eradication.
Collapse
Affiliation(s)
- Vanna Sanna
- Department of Chemistry and Pharmacy, Laboratory of Nanomedicine, University of Sassari, Sassari, Italy
| | - Nicolino Pala
- Department of Chemistry and Pharmacy, Laboratory of Nanomedicine, University of Sassari, Sassari, Italy
| | - Mario Sechi
- Department of Chemistry and Pharmacy, Laboratory of Nanomedicine, University of Sassari, Sassari, Italy
| |
Collapse
|